NCCN: Cancer and COVID-19 Vaccination Version 1.0, January 22

Preliminary Recommendations of the NCCN COVID-19 Vaccination Advisory Committee

* Patients with cancer should be prioritized for vaccination (CDC priority group 1b/c) and should be immunized when vaccination is available to them.

* Immunization is recommended for all patients receiving active therapy, with the understanding that there are limited safety and efficacy data in these patients.

* Reasons for delay of vaccines are similar to the general public (e.g., recent exposure to COVID-19), and cancer-specific factors. Vaccination should be delayed for at least 3 months following HCT or engineered cellular therapy (e.g. CAR-T cells) to maximize vaccine efficacy.

* Caregivers and household/close contacts should be immunized when possible.

1) Prioritize patients with active cancer on treatment (including hematopoietic and cellular therapy), those planned to start treatment and those immediately (<6 months) post- treatment, except those receiving only hormonal therapy.

2) Consider additional risk factors for such patients and other factors linked to adverse COVID- 19 complications including but not limited to:

* Patients with advanced age (e.g., ≥65 years of age)

* Patients with co-morbidities (e.g. chronic pulmonary, cardiovascular or renal disease)

* Social and demographic factors that include poverty, limited access to healthcare, and under-represented minorities